Research project to develop temperature-adjustable retina laser launched

Article

A research project developing new technologies for laser treatments for the retina has been launched by the German Federal Ministry for Education and Research.

A research project developing new technologies for laser treatments for the retina has been launched by the German Federal Ministry for Education and Research. Collaboration partners on the project include Carl Zeiss Meditec, the Medical Laser Center, Lübeck, the Institute of Biomedical Optics of the University of Lübeck and the Eye Clinic of the University Hospital of Schleswig-Holstein, Germany.

The research project aims to develop a method for targeting precise doses of laser radiation to specific areas within the eye. The doses will be set automatically, to be as low as possible to reduce or eliminate side effects whilst being high enough to be optimally effective to conduct the treatment. The adjustable-temperature laser is intended to treat diseases such as diabetic retinopathy that affect a large portion of the retina.

The project was selected as the winner of the Ministry for Education and Research's "Innovation Competition for the Advancement of Medical Technology", and is anticipated to run for three years.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.